Skip to main content

Schwannomatosis

1
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
TanezumabPhase 2Monoclonal Antibody3 trials
Active Trials
NCT04163419Unknown9Est. Sep 2024
NCT00809354Terminated2,720Est. Jan 2011
NCT00669409Completed83Est. Dec 2009
Recordati
RecordatiFrance - Saint-Victor
1 program
SiltuximabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT05684692Recruiting40Est. Nov 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
PfizerTanezumab
RecordatiSiltuximab
PfizerTanezumab
PfizerTanezumab

Clinical Trials (4)

Total enrollment: 2,852 patients across 4 trials

NCT00809354PfizerTanezumab

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

Start: Feb 2009Est. completion: Jan 20112,720 patients
Phase 3Terminated
NCT05684692RecordatiSiltuximab

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Start: Aug 2023Est. completion: Nov 202740 patients
Phase 2Recruiting
NCT04163419PfizerTanezumab

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Start: Apr 2020Est. completion: Sep 20249 patients
Phase 2Unknown
NCT00669409PfizerTanezumab

A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee

Start: Jun 2008Est. completion: Dec 200983 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,852 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.